Monopar Therapeutics (NASDAQ:MNPR) Stock Jumps 3.1% – Time to Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s share price traded up 3.1% on Wednesday. The stock traded as high as $82.32 and last traded at $82.04. 20,994 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 210,178 shares. The stock had previously closed at $79.57.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on MNPR shares. Zacks Research lowered Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Barclays reaffirmed an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Cantor Fitzgerald downgraded shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Morgan Stanley restated an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Finally, Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.00.

Monopar Therapeutics Price Performance

The stock has a fifty day simple moving average of $106.02 and a two-hundred day simple moving average of $83.16. The firm has a market capitalization of $569.18 million, a P/E ratio of -39.09 and a beta of 1.50.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, sell-side analysts expect that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other news, Director Christopher Starr sold 8,400 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $78.50, for a total transaction of $659,400.00. Following the transaction, the director owned 5,173 shares in the company, valued at approximately $406,080.50. This represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the transaction, the chief executive officer directly owned 99,267 shares in the company, valued at $8,735,496. This trade represents a 22.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 44,688 shares of company stock valued at $4,023,094. 9.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in Monopar Therapeutics in the 2nd quarter valued at $7,124,000. Bank of America Corp DE raised its holdings in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Monopar Therapeutics during the first quarter valued at about $250,000. Finally, Siren L.L.C. grew its holdings in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the last quarter. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.